Research programme: neurodegenerative therapeutics - Schering-Plough/Amgen
Latest Information Update: 09 Sep 2008
Price :
$50 *
At a glance
- Originator Amgen; Schering-Plough
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Neurological disorders
Most Recent Events
- 22 Feb 2005 NeoGenesis has been acquired and merged into Schering-Plough
- 06 Aug 2003 Preclinical trials in Neurological disorders in USA (unspecified route)